Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SPRUCE BIOSCIENCES, INC.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.70 · Expires 2036-05-20 | Direct | 1,700 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,700 · Balance 1,700 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 20:30 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $52.70 | $0.00 |
DisclosureSEC source: 0001978654-26-000002 · form4-05262026_040503.xml · derivative · entry 1 Barretto-Ko Percival · CIK 0001978654 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:47 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerStock Option (Right to Buy) · Derivative | 800 | Not disclosed Strike: $169.50 | Not disclosed |
DisclosureSEC source: 0001978654-25-000003 · form4-12152025_111234.xml · derivative · entry 2 Barretto-Ko Percival · CIK 0001978654 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800 shares Expires 2033-05-24 F1 · derivative.exercise_price: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of May 25, 2023, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:47 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 800 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001978654-25-000003 · form4-12152025_111234.xml · derivative · entry 1 Barretto-Ko Percival · CIK 0001978654 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2033-05-24 F1 · shares: Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five. F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F2 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of May 25, 2023, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 23:36 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001415889-25-020267 · form4-07242025_110706.xml · derivative · entry 1 Barretto-Ko Percival · CIK 0001978654 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-07-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:24 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-014489 · form4-05242024_080535.xml · derivative · entry 1 Barretto-Ko Percival · CIK 0001978654 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-21 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:35 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001209191-23-032647 · doc4.xml · derivative · entry 1 Barretto-Ko Percival · CIK 0001978654 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the Grant Date, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.